GSK to work with antisense firm Isis on rare and infectious diseases

Isis Pharmaceuticals has secured a collaboration deal with GlaxoSmithKline which will see the latter pay $35 million in upfront cash and additional milestones in return for an option to license up to six anti-RNA therapeutic compounds at Phase II proof of concept. The deal covers rare and infectious diseases, and the targets will be contributed by GSK.